This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers | MicrobiomeTrials
← Back to trials NCT06128382
First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers Completed PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-01-08Est. Completion: 2024-07-08
Enrollment target: 48 participantsLocations CIC Cochin Pasteur CIC 1417 Hôpital Cochin, Paris, France Other microbiome trials you might be interested in COVID-19
This study evaluates the community-based health education program in improving early testing for COVID-19, increasing va…
Hung Hom, Hong Kong Completed Oct 31, 2025
Coronavirus Disease 2019
Background:
COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the number of cells ca…
Washington D.C., United States Completed Feb 20, 2025
Anxiety
Health-Related Behavior
Healthy Lifestyle
Healthy Nutrition
Healthy Diet
Health Behavior
Choice Behavior
The aim of this 3-phase study is the evaluation of planetary health behaviors and its cognitive processes in relation to…
Bremen, Germany Completed Dec 31, 2024